Published in Vaccine Weekly, October 10th, 2001
A team led by researchers at the National Human Genome Research Institute of Bethesda, Maryland, has reported gene therapy vectors expressing herpes simplex thymidine kinase (HSVtk) tend to boost some parts of the immune system, essentially preventing the formation of new tumors as well as killing existing tumors.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.